A positive opinion from an EU drug committee put Revolution Medicines in the headlines, but the available information doesn’t spell out the recommendation’s terms or what happens next.
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended marketing authorization for Revolution Medicines’ daraxonrasib to treat metastatic pancreatic cancer. An Oct. 17 headline highlighted the news. The available information doesn’t include details of the recommendation, a final authorization decision, or a company statement.
Investor takeaway: The CHMP opinion is a regulatory milestone. The timing and outcome of any final EU authorization remain unknown.
Advertisement
Revolution Medicines Inc
RVMD.US
RVMD.US
Revolution Medicines Inc
WealthAwesomeMarket cap
$39.04B
52W high
$224.31
52W low
$52.48
1W change
-6.08%
Beta
1.40
Analyst Price Targets
Based on 24 analysts covering RVMD · as of Oct 20, 2026
Wall Street analysts forecast RVMD stock price to rise 41.6% over the next 12 months.
Consensus
Strong Buy4.71 / 5.00
Avg. Target
C$257.84
+41.6% Upside
Previously C$257.80 on Oct 19, 2026
Current Price
C$182.15
Last close
Analyst Breakdown (24 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on RVMD's historical volatility
30-Day Vol
40.8%
Annualized
90-Day Vol
40.0%
Annualized
Trend (90d)
-16.0%
Annualized drift
90d Mean
C$172.02
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$178.71 | C$155.22 – C$205.76 |
| 60 trading days | C$175.33 | C$143.65 – C$214.01 |
| 90 trading days | C$172.02 | C$134.77 – C$219.58 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Shares closed at US$182.15
RVMD gained 2.35% on the day. Reported volume was 1,321 shares, compared with a 20-day average of 2,222,487. The available figures don’t show whether the EU news affected the share price.
Bull case
The company-news headline reports a positive CHMP opinion recommending EU marketing authorization for daraxonrasib in metastatic pancreatic cancer. That’s a concrete regulatory development for Revolution Medicines.
Bear case
A committee recommendation doesn’t confirm final EU marketing authorization. The available information also gives no further details about the opinion or its implications.
What happened: CHMP recommended EU marketing authorization
A company-news item dated Oct. 15 says Revolution Medicines’ RASONQUE™ (daraxonrasib) received a positive CHMP opinion recommending marketing authorization in the European Union for metastatic pancreatic cancer. An Oct. 17 headline summarized the news as EU drug backing.
The available information doesn’t say whether the European Commission has made a final decision, when it might do so, or what conditions the recommendation includes. It also provides no trial results or other clinical details, so those can’t be assessed here.
Advertisement
What the numbers show: a higher close on very low reported volume
Revolution Medicines closed at US$182.15, up 2.35% for the day. Reported volume was 1,321 shares, compared with a 20-day average of 2,222,487 shares. The supplied volume comparison is 0.89x. The figures don’t explain the reported volume or show that the regulatory news drove the day’s move.
The close was 10.3% below the US$203.12 50-day moving average and 20.1% above the US$151.62 200-day average. Shares stood at 75% of their US$52.48–US$224.31 52-week range. These figures describe recent trading, not the reason for the price change. See the RVMD.US stocks page for the supplied quote information.
What to watch next: whether the recommendation leads to authorization
The next key question is whether the CHMP recommendation leads to a final EU marketing authorization. The available information gives no decision date or further regulatory milestones, so the timing is unknown.
The company’s RVMD.US stocks page also lists a 0.0% profit margin and negative trailing EPS of US$8.87. These figures provide company context but don’t clarify the regulatory outcome.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
